HomeCONGRESS

CONGRESS

View Category
Day 2

HATTRICK-OCT: biodegradable polymer struts coverage versus permanent

Late endothelialization of first generation pharmacological stents may predispose thrombosis. Both the drug and the polymer of...
solaci -
Learn More
Day 1

EnligHTN: treatment of refractory hypertension by catheterization

Lowering blood pressure with renal denervation has been demonstrated in previous studies but unfortunately there was not...
solaci -
Learn More
Day 1

SOURCE XT: Results of the latest generation of the Edwards valve

The first generation of the Edwards valve was stainless steel and bovine pericardium with a profile of...
solaci -
Learn More
Day 1

SCAAR: Heparin versus bivalirudin in patients with myocardial infarction without ST segment elevation.

We evaluated 41,537 patients admitted with myocardial infarction without ST elevation on the SCAAR register and who...
solaci -
Learn More
Day 2

DEMONSTR8: better endothelial coverage by OCT for the new DES

There is still concern about the safety of drug-eluting stents (DES) due to the possibility of late...
solaci -
Learn More
Day 2

BIOSS: results of the new drug-eluting stent for bifurcations

This new device is a stainless steel platform of 120 µm thick with a sirolimus-eluting bio-absorbable polymer....
solaci -
Learn More
Day 2

CENTURY: new clinical results of sirolimus-eluting degradable polymer stent

This new stent is a sirolimus-eluting low-profile cobalt chrome platform (80 µm) with a rapid resorption polymer...
solaci -
Learn More
Day 1

DESolveNx trial: Results of the new bioabsorbable platform

This new device consists of a novolimus releasing bioabsorbable polylactic acid platform that in vitro studies has...
solaci -
Learn More